CL2017002474A1 - Combinaciones antihelmínticas y los métodos de usos de las mismas - Google Patents

Combinaciones antihelmínticas y los métodos de usos de las mismas

Info

Publication number
CL2017002474A1
CL2017002474A1 CL2017002474A CL2017002474A CL2017002474A1 CL 2017002474 A1 CL2017002474 A1 CL 2017002474A1 CL 2017002474 A CL2017002474 A CL 2017002474A CL 2017002474 A CL2017002474 A CL 2017002474A CL 2017002474 A1 CL2017002474 A1 CL 2017002474A1
Authority
CL
Chile
Prior art keywords
methods
prophylaxis
treatment
macrocyclic lactone
anthelmintic
Prior art date
Application number
CL2017002474A
Other languages
English (en)
Inventor
Brenda Bondesen
Lance Hammerland (Fallecido)
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57006415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002474(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Inc filed Critical Merial Inc
Publication of CL2017002474A1 publication Critical patent/CL2017002474A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención se relaciona con una composición veterinaria comprendiendo una cantidad efectiva de al menos un depsipéptido cíclico y al menos una lactona macrocíclica; y un vehículo farmacéuticamente aceptable, para el tratamiento o profilaxis de la infección parasítica en un mamífero donde el parásito muestra resistencia a tratamiento o profilaxis con la lactona macrocíclica sola.</p>
CL2017002474A 2015-04-02 2017-10-02 Combinaciones antihelmínticas y los métodos de usos de las mismas CL2017002474A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562142304P 2015-04-02 2015-04-02

Publications (1)

Publication Number Publication Date
CL2017002474A1 true CL2017002474A1 (es) 2018-03-23

Family

ID=57006415

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002474A CL2017002474A1 (es) 2015-04-02 2017-10-02 Combinaciones antihelmínticas y los métodos de usos de las mismas

Country Status (18)

Country Link
US (1) US10993988B2 (es)
EP (1) EP3277303B1 (es)
JP (1) JP6899330B2 (es)
KR (1) KR20170132330A (es)
CN (1) CN107567334A (es)
AU (1) AU2016244022A1 (es)
BR (1) BR112017020975A2 (es)
CA (1) CA2981489A1 (es)
CL (1) CL2017002474A1 (es)
CO (1) CO2017011284A2 (es)
ES (1) ES2851345T3 (es)
IL (1) IL254783B (es)
MX (1) MX2017012510A (es)
MY (1) MY187835A (es)
PH (1) PH12017501806A1 (es)
RU (1) RU2717545C2 (es)
SG (1) SG11201708008TA (es)
WO (1) WO2016161369A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018093920A1 (en) * 2016-11-16 2018-05-24 Merial, Inc. Anthelmintic depsipeptide compounds
PT3579696T (pt) * 2017-02-08 2023-07-19 Boehringer Ingelheim Animal Health Usa Inc Modelo in vivo para infeção por vermes parasitários e métodos para avaliação de compostos antiparasíticos, que incluem compostos ativos contra a dirofilariose canina
BR112020010291A2 (pt) 2017-11-23 2020-11-17 Ceva Sante Animale composição contendo moxidectina para tratamento de infestações de parasitas
US11331369B2 (en) * 2017-11-29 2022-05-17 Zoetis Services Llc Endoparasitic depsipeptides
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos
CA3236894A1 (en) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
GB9300883D0 (en) 1993-01-18 1993-03-10 Pfizer Ltd Antiparasitic agents
DE19520275A1 (de) * 1995-06-02 1996-12-05 Bayer Ag Endoparasitizide Mittel
US20030129680A1 (en) 2001-10-31 2003-07-10 O'connor Thomas Patrick Multi-analyte assay device
US20070042354A1 (en) 2005-08-19 2007-02-22 Engelhard Eric K Detecting pathogens in companion animals
ES2367332T3 (es) * 2007-02-21 2011-11-02 Pfizer Limited Agentes antiparasitarios de benzofurano.
JP4734656B2 (ja) 2007-03-30 2011-07-27 国立大学法人群馬大学 Ｐｆ１０２２類の製造法
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US8809268B2 (en) 2008-10-29 2014-08-19 The Regents Of The University Of California Combination therapy to combat helminth resistance
BE1019407A5 (nl) 2009-11-06 2012-07-03 Momentum Animal Cure Bvba Middel voor het uitdrijven van parasieten bij mensen, dieren en vogels.
EP2531506B1 (en) 2010-02-05 2014-05-14 Intervet International B.V. Spiroindoline compounds for use as anthelminthics
WO2011115840A2 (en) 2010-03-14 2011-09-22 Ibis Biosciences, Inc. Parasite detection via endosymbiont detection
RU2452180C2 (ru) 2010-08-31 2012-06-10 Общество с ограниченной ответственностью "Научно-внедренческое предприятие "Астрафарм" Комплексная антипаразитарная композиция
AU2010249226C1 (en) 2010-12-08 2017-04-13 Zoetis Services Llc Anthelmintic formulation
AU2010101389C4 (en) 2010-12-08 2017-03-02 Jurox Pty Ltd Anthelmintic formulation
WO2013017678A1 (en) 2011-08-04 2013-02-07 Intervet International B.V. Novel spiroindoline compounds

Also Published As

Publication number Publication date
JP6899330B2 (ja) 2021-07-07
JP2018510195A (ja) 2018-04-12
MY187835A (en) 2021-10-26
CO2017011284A2 (es) 2018-01-31
EP3277303A1 (en) 2018-02-07
CA2981489A1 (en) 2016-10-06
IL254783A0 (en) 2017-12-31
SG11201708008TA (en) 2017-10-30
AU2016244022A1 (en) 2017-10-26
EP3277303B1 (en) 2020-12-02
RU2717545C2 (ru) 2020-03-24
BR112017020975A2 (pt) 2018-07-10
RU2017138118A3 (es) 2019-07-24
IL254783B (en) 2020-11-30
MX2017012510A (es) 2018-01-30
US10993988B2 (en) 2021-05-04
KR20170132330A (ko) 2017-12-01
RU2017138118A (ru) 2019-05-06
WO2016161369A1 (en) 2016-10-06
ES2851345T3 (es) 2021-09-06
US20170020955A1 (en) 2017-01-26
CN107567334A (zh) 2018-01-09
PH12017501806A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
CL2017002474A1 (es) Combinaciones antihelmínticas y los métodos de usos de las mismas
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CL2017003404A1 (es) Compuestos antibacterianos
UY37563A (es) Aislados de bacillus y usos de los mismos
CO2017001035A2 (es) “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios
CO7350655A2 (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2014003509A1 (es) Composición veterinaria masticable blanda que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal (div. sol. n°2087-14).
CL2012002782A1 (es) Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros.
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
CU20170153A7 (es) Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
CL2018000253A1 (es) Respuesta inmunitaria potenciada de las especies porcinas
PE20151726A1 (es) Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles